July 12, 2021

GeparNUEVO: durvalumab plus neoadjuvant chemotherapy in TNBC demonstrates long-term clinical benefit

There was a small increase in pCR initially (with no continuity after surgery), questioning the need to maintain immunotherapy as adjuvant treatment, according to data presented in ASCO 2021  During ASCO World Congress […]
July 7, 2021

CheckMate 648: first-line immunotherapy as a new standard of care for advanced esophageal SCC

Nivolumab demonstrated superior overall survival versus chemotherapy in patients with previously treated esophageal squamous cell carcinoma, according to ATTRACTION-3 data. At ASCO 2021, immunotherapy efficacy data were released in the first–line setting of Checkmate […]
July 7, 2021

Real-world assessment of biomarker testing in patients with untreated metastatic NSCLC in U.S. community practices

Given the importance of molecular testing and target therapy for the treatment of metastatic NSCLC, it is essential to understand how testing has been performed in clinical practice […]
July 6, 2021

FUTURE-C-PLU evaluates the combination of famitinib with camrelizumab plus nab-paclitaxel as 1st line treatment for patients with advanced TNBC

Camrelizumab and nab-paclitaxel demonstrated promising antitumor activity in immunomodulatory triple-negative metastatic breast cancer (TNBC) patients in FUTURE trial, but the efficacy of adding famitinib to this strategy is under investigation    During […]
July 6, 2021

Updated efficacy and safety data from the CheckMate 577 trial

Nivolumab is known to demonstrate significant improvement in disease-free survival versus placebo in patients with resected stage II/III esophageal cancer with residual pathologic disease after neoadjuvant chemoradiotherapy, according to a recent publication in NEJM  […]
July 5, 2021

Largest real-world dataset on small cell lung cancer subtypes reveals different expression of clinically relevant biomarkers

This is the largest real-world analysis of SCLC evaluated by whole transcriptome sequencing  The dominant expression of four lineage-defining transcription factors (ASCL1, NEUROD1, YAP1 or    POU2F3) allows the classification of small cell […]
July 5, 2021

Efficacy of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer with brain metastases.

Patients with HER2+ metastatic breast cancer are at high risk of developing brain metastases and treatment options are limited when secondary involvement lesions arise in the […]
July 2, 2021

Final KEYNOTE 177 overall survival data for MSI-H/dMMR metastatic colorectal cancer

Pembrolizumab versus chemotherapy showed progression-free survival improvement in the second provisional analysis in patients with the tumor. The study continued until the final overall survival (OS) analysis, planned after 190 OS events […]
July 2, 2021

VISION: Phase III trial demonstrates 177Lu-PSMA-617 is the new standard of care for men with advanced mCRPC

The 177Lu-PSMA-617 is a targeted radioligand therapy that distributes ß–particle radiation to cells expressing PSMA and to the surrounding microenvironment    During the ASCO World Congress 2021, VISION (NCT03511664), an international, randomized, open-label phase […]